Imugene Ltd (ASX: IMU) chief operating officer Brad Glover and CEO Leslie Chong sit down with Proactive’s Tylah Tully to discuss positive results from its Phase 1b clinical trial of azer-cel (azercabtagene zapreleucel), an allogeneic off-the-shelf CD19 CAR T therapy, in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL). This trial addresses a significant unmet need as all participants had cancer that returned after autologous CAR T therapy. Ten patients have been treated, divided into two cohorts. Cohort A involved six patients treated with azer-cel and lymphodepletion chemotherapy. Cohort B included four patients who received azer-cel, lymphodepletion chemotherapy, and interleukin 2 (IL-2). Results showed three complete responses, with two in Cohort B and one in Cohort A. The complete responses in Cohort B have been durable, with one exceeding 120 days and another more than 90 days. All four patients in Cohort B remain in the trial, and more patients will be enrolled. The treatment has been safe and tolerable. The promising results from Cohort B will be included in the potential FDA Phase 2/3 registration package. Imugene plans to continue patient enrolment and further explore the therapy's potential, including future studies combining azer-cel with its onCARlytics program for solid tumours. #ProactiveInvestors #Imugene #ASX #ClinicalTrial #AzerCel #CAR_T #DLBCL #NonHodgkinsLymphoma #CancerResearch #Oncology #FDAApproval #MedicalResearch #BloodCancer #LymphomaTreatment #Biotechnology #Immunotherapy #Phase1b #CompleteResponse #PatientCare #MedicalBreakthrough #SolidTumors #OnCARlytics #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews